title: [Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
abstract: Rebamipide, a cytoprotective agent, has been suspected to attenuate oral mucositis through anti-inflammatory potentials and induction of endogenous prostaglandin synthesis. This prospective study was designed to assess the clinical efficacy of rebamipide gargle against oral mucositis, which is induced by fluoropyrimidines in patients with stomach and colorectal cancer. We first conducted a pilot study on gargle flavors, because the solution in this agent has a strong and bitter after taste. Nine kinds of flavors were prepared, and six characteristics were evaluated by ten volunteers: sourness, bitterness, sweetness, remain, after taste, and hard to drink. We determined the contents of rebamipide using HPLC, which showed stability in an acidic condition. Finally, we decided that 100% Pokka Lemon should be used as the flavor of the rebamipide solution. A clinical study was then started to compare the preventive effects rebamipide gargle and placebo have on stomatitis, quality of life (QOL), and the therapeutic effects of chemotherapy.
authors.affiliation: Dept. of Hospital Pharmacy, Nagoya Memorial Hospital, Japan.
authors.forename: Megumi
authors.initials: M
authors.lastname: Kabeya
authors.forename: Kenji
authors.initials: K
authors.lastname: Ina
authors.forename: Shu
authors.initials: S
authors.lastname: Yuasa
authors.forename: Fumi
authors.initials: F
authors.lastname: Kikuchi
authors.forename: Chiharu
authors.initials: C
authors.lastname: Tajiri
authors.forename: Tae
authors.initials: T
authors.lastname: Kato
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hibi
authors.forename: Yoko
authors.initials: Y
authors.lastname: Minagawa
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Furuta
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kayukawa
authors.forename: Takae
authors.initials: T
authors.lastname: Kataoka
authors.forename: Masaru
authors.initials: M
authors.lastname: Kawai
mesh_terms: D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy; D005472:Fluorouracil / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009067:Mouthwashes / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D011446:Prospective Studies; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy; D013280:Stomatitis / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D009067:Mouthwashes; D015363:Quinolones; C052785:rebamipide; D000409:Alanine; D005472:Fluorouracil